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  ABSTRACT 
BACKGROUND 
 Study aimed to evaluate a novel patient-held manual designed to reduce the evidence-
practice gap in COPD (chronic obstructive pulmonary disease). 
 Primary hypothesis: After 12 months COPD management will be more consistent with 
evidence for patients given the manual when compared with patients given a widely 
available COPD information leaflet.  
METHODS - DESIGN 
 Intervention manual contained summaries of research evidence. Manual was developed 
using current best practice for patient information materials and designed to cause 
discussion of evidence between patient and doctor. 
 Controlled before-and-after study, using two similar but geographically separate regions 
of metropolitan Adelaide, South Australia.  
METHODS - PARTICIPANTS  
 People with moderate to severe COPD.  
 Entering study: 249 participants. 
 Completing study: 201 participants. 
METHODS - MEASURES  
 Main outcome: Indicator of evidence based COPD management made up of three 
components which were rates of influenza vaccination, bone density testing and 
pulmonary rehabilitation.  
 Processes evaluation. Survey of behavioural steps leading to practice change. 
RESULTS  
 Main outcome: Analysis, by median split of socio-economic disadvantage, showed 
significant difference between study arms for only one component of the indicator of 
evidence based practice, enrolment in pulmonary rehabilitation and only in the most 
socio-economically disadvantages stratum. 
  
 Processes evaluation: For both socio-economic strata, more intervention than control 
participants reported remembering being given the information material, reading part or 
all, and finding it very or quite helpful. Other significant differences were restricted to the 
stratum of greatest socio-economic disadvantage: reading all of the material, learning 
from it, referring back, and talking to a doctor about a topic from the material. 
 Over 90% of all participants who received the manual reported reading from it, 42% 
reported discussing topics with a doctor, but only 10% reported treatment change 
attributable to the manual.  
CONCLUSIONS  
 We have found that people with COPD will read an evidence manual developed using 
current best practice. However, the study demonstrated improvement for only one of the 
three components of an indicator of evidence-based disease management, for only the 
most socio-economically disadvantaged stratum of participants Future interventions 
should be designed to better translate reading uptake into evidence-based disease 
management. 
 
 INTRODUCTION 
Strategies to reduce the gap between research evidence and clinical practice have the 
potential to greatly improve health outcomes.
1
 Most strategies to date have targeted 
health professionals only. They have improved practice to some extent but many have 
not been cost effective and results have been inconsistent from study to study.
2
. There 
have been fewer studies of strategies which include patients.
2
 In most of these studies 
the patient has not been informed about evidence; their role has been as delivery 
channel for reminders to the doctor. Patients are increasingly expected to participate 
in decision making and disease management, especially in chronic disease, therefore 
research is needed on strategies which provide patients with their own reviews of 
evidence and encourage them to discuss this evidence with their doctors.   We 
conducted a study of patients with COPD who were give a manual which contained 
summaries of the evidence for treatments used in COPD and gave suggested opening 
questions for discussing this evidence with doctors. The manual was a relatively low-
cost intervention, developed using current best practice regarding information 
presentation and terminology for patient information materials.
4
 The study assessed 
the impact of this manual on clinical decisions. Initial 3 month assessment showed 
little treatment change,
5
 but a longer period is probably required to demonstrate 
benefits, such as improved vaccination rates, from this type of intervention. We now 
report results at 12 months. 
STUDY AIMS 
The aim of this study was to show whether providing summaries of evidence to 
people who have COPD leads to improved application of that evidence in their 
medical care. Application of evidence was measured using three evidence-supported 
medical interventions for COPD: influenza vaccination,
6
 bone density testing,
7,8
  
  
and pulmonary rehabilitation.
9
 
The evaluation of the manual included an assessment of outcomes and a process 
evaluation. A survey of all participants was part of the process evaluation and is 
reported here. 
HYPOTHESIS 
The primary hypothesis to be tested was: 
Compared with patients who have been given a conventional pamphlet, patients who 
have been given the COPD Evidence Manual will have increased self-reported rates for 
each of the following: 
a) rate of influenza vaccination within the previous 15 months (allowing a 3 month 
delay in obtaining an annual vaccination) 
b) rate of bone density testing within the previous 42 months (allowing a 6 month 
delay in 3-yearly testing) 
c) enrolment in pulmonary rehabilitation after receiving the manual 
 
While it was not primarily designed to increase patient mastery and knowledge of 
COPD, patient communication with the regular doctor, and patient satisfaction s with 
provision of information, we wished to ascertain whether the manual improved these 
outcomes. Disease-related information can cause anxiety if provided insensitively and 
while checks and adjustments were made during preparation of the manual to avoid 
causing distress, we also wished to ensure that the manual did not increase anxiety. 
The following additional outcome measures were therefore included:  
 mastery of COPD, as measured by the Mastery domain of the Chronic Respiratory 
Questionnaire (CRQ)
10
 
 knowledge of COPD, as measured by a test adapted from Hermiz et al11 
 communication with usual doctor, as measured by the Communication and Comfort and the 
Rapport subscales of the Medical Interview Satisfaction Scale (MISS)
12
(slightly modified to 
exclude questions inapplicable in COPD) 
 satisfaction with disease related information, as measured using the question “I have enough 
information about my lung condition” and the response options scale from the MISS 
 anxiety, as measured by the Short-form Spielberger State Anxiety Inventory13 
METHODS 
The intervention manual 
The study trialled a manual for patients which summarised Cochrane Reviews of 
evidence about COPD treatments, and provided additional background topics.
4
 To 
 encourage discussion of evidence with doctors, a tip or a suggested question that a 
patient could ask their doctor accompanied each summary. Questions were used, 
rather than overt requests to consider evidence, in keeping with usual patient 
behaviour in consultations.
14
 The manual used very plain language, lay terminology, 
small page size and large print, question-and-answer format, and illustrations of 
people with COPD engaging in activities of daily living as well as in clinical settings.  
Research-based recommendations on the design of patient information materials were 
used as a guide to design of the manual, 
15,16
 though we noted that these 
recommendations were based on measures of patient satisfaction rather than health 
outcomes or behaviours.  
Of a total of 22 reviews, 16 were based on Cochrane reviews with others based on 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
17
 or 
comprehensive reviews from journals.
7
 
Recruitment 
Patients with moderate to severe COPD were sought (according to GOLD criteria). 
Patients were excluded if they also had lung cancer, dementia or other major, 
currently unstable illness, and if the patient or carer didn’t have at least a basic ability 
to read English.  
Potential participants were identified through in-patient admission for COPD and at 
respiratory outpatient clinics at 3 teaching hospitals in Adelaide, South Australia. 
Invitations, signed by the patient’s doctor, were mailed to patients after discharge, or 
handed to the patient by the doctor at clinic. A reminder was sent if there was no 
response after 3 weeks. Recruitment continued progressively from 04/03/2003 to 
05/03/2005. 
  
Allocation and blinding 
Contamination of the control group, both patient to patient and via a doctor, was 
likely with this intervention. A controlled before-and-after design was therefore 
adopted, using patients from two geographically separate areas of metropolitan 
Adelaide, South Australia. The two areas appeared demographically similar
18
 and 
each was served by a large public hospital providing a similar range of services with 
occasional exchange of medical staff. Control participants received a simple, single 
sheet fold-out pamphlet containing information about COPD
19
 in keeping with usual 
practice. 
Because of the nature of the intervention and allocation, interviewers could not be 
blinded but they were trained to administer questionnaires, record answers, and give 
the information materials in a consistent way. Participants were blind to their 
intervention/control status because study explanation stated that different types of 
information were being tested and that each participant would receive one type at 
first, and the other at the end of the study. 
Data collection and delivery of intervention 
Data was collected by interviewer administration, and the intervention manual and 
control pamphlet were handed to participants at the end of baseline data collection. 
Participants’ general practitioners (GPs) received prior information about the trial 
through local general practice organisations. In addition, intervention participants 
were given an order form which they could hand to their GP so that the GP could 
order a free copy of the manual.  
Baseline comparisons 
Baseline comparison between groups was made using the outcome measures (given 
below) and additional demographic and disease-related variables which were 
 potentially associated with use of the manual: gender, use of oxygen therapy (as 
indicator of severity of COPD), smoking status, age, years of formal education, Index 
of Relative Socio-Economic Disadvantage for postcode,
20
 living alone, overall score 
for the Medical Interview Satisfaction Scale,
12
 and dyspnoea, fatigue and emotional 
function domains of the CRQ.
10
 
Sample size 
As shown in Table 1, the calculated minimum sample size was 98 participants per 
arm. To allow for some loss of participants and other possible factors (eg. adjustment 
for any group differences) our recruitment target was 120 per arm. 
Process measures  
The hypothesised link between provision of the manual and improved COPD 
management implied a series of causal steps including: reading by the patient, 
discussion at a consultation, and treatment change. Steps are shown in Figure 1. At 12 
months, participants were asked a series of closed survey questions to assess each of 
these steps.  
Analysis and imputation 
Baseline demographic and clinical comparisons were made using the chi-square test 
for dichotomous variables, or Fisher’s exact test if numbers in any cells were less than 
5, and Student’s t test for continuous variables.  
For all outcomes except enrolment in pulmonary rehabilitation, change scores to 12 
months were analysed using analysis-of-covariance, with adjustment for baseline 
score, to remove the effect of regression to the mean. Poisson modelling was used to 
compare proportions attending pulmonary rehabilitation. If any baseline difference 
was found, adjustment by propensity scoring
21
 was planned. The conventional 0.05 
probability level for statistical significance was used throughout. Missing interviews 
  
were excluded from analysis. Missing data elements (needed only for the Medical 
Interview Satisfaction Scale which contained 5.1% missing data) were imputed by 
expectation-minimisation imputation and used SPSS 12 For Windows software. Data 
were otherwise analysed using Stata 8.2 software. 
RESULTS 
Participant flow 
Numbers of participants at each stage of the trial are shown in Figure 2 
Baseline comparisons 
Table 2 shows baseline demographic and clinical comparisons. Intervention and 
control groups were similar, apart from measures of socio-economic disadvantage,
14
 
previous attendance at pulmonary rehabilitation and living alone. A propensity score 
was therefore created for each participant by including all baseline measures in a 
logistic regression with the grouping variable as the dependent variable. This score 
was included in analysis-of-covariance models for outcomes to adjust for baseline 
differences.
21
 Propensity score means were 0.75 for intervention participants and 0.24 
for control participants. Socio-economic disadvantage appeared to be an effect 
modifier therefore subsequent outcomes analyses were done using median split of this 
variable, which had the effect of reducing the power of the study. 
Outcomes  
Outcome measures at 12 months are shown in Table 3. One of the three components 
of the primary outcome measure, enrolment for pulmonary rehabilitation, showed 
significant change for the most socioeconomically disadvantaged stratum. There was 
a non-significant trend in the same direction for pulmonary rehabilitation in the most 
socioeconomically advantaged stratum. There were no other significant differences 
and few trends in favour of either group for primary and secondary outcomes. 
 Processes 
Process survey results are shown in Table 4. For both socio-economic strata, 
significantly more intervention than control participants reported that they 
remembered receiving the information material, read part or all of it and found it very 
or quite helpful. Other significant differences were restricted to the stratum with 
greatest socio-economic disadvantage. More intervention participants in this stratum 
reported that they read all of the material, learned from it, referred back after first 
reading and talked to a doctor about a topic from the material. For all other 
comparisons, non-significant trends showed greater completion of process steps by 
intervention participants. 
 
Figure 3 shows an examination of process steps for the complete intervention group 
only. Over 90% of participants who received the manual reported reading at least 
some of it. Forty two percent reported talking to their doctor about a topic from the 
manual but only 10% reported that this led to treatment change.  
DISCUSSION 
Findings 
The study did not find that providing summaries of evidence to people with COPD led 
to improved application of evidence in their medical care.  
However, the study did find that a patient-held manual containing summaries of 
evidence, which was developed using current best practice, was more likely than a 
conventional pamphlet to be remembered, read and considered helpful by people with 
COPD. People with greatest socio-economic disadvantage reported greatest use of the 
manual. Interestingly, about half of the people who read the manual subsequently 
discussed a related topic with their doctor but very few reported treatment change 
attributable to the manual. This suggests that that either these discussions were not 
  
patient requests for treatment change, or if they were, that doctors did not make the 
treatment changes requested by patients.  
Comparison with findings of other studies 
A comprehensive review found a lack of other studies on the effects of patient-held 
evidence summaries on clinical decisions in chronic disease.
22
 
However, there have been outcome and process evaluations of other kinds of 
information materials for people with chronic disease,
22
 and of evidence based 
information for other target audiences.
23
 Best practice development methods do not 
appear to have been used for most of these materials and they had little success in 
influencing the behaviour of target audiences and their doctors. An exception is a 
guidebook for people with irritable bowel syndrome, developed using current best 
practice, and found to reduce primary care consultations and perceived symptom 
severity.
24 
 
Limitations 
Some design limitations of our study may have meant that some positive outcomes 
were not detected. 
Only three aspects of COPD management were measured for the primary outcome. 
Other, unmeasured changes, may have been prompted by the manual. The duration of 
the trial may have been insufficient to demonstrate change because only a few of the 
evidence summaries would be relevant to any one participant over a 12-month period. 
Higher than expected baseline rates among people who volunteered for the study for 
components of the measure of best practice had the effect of reducing the power of 
the study. The need to stratify analyses and to include propensity scores to adjust for 
unforseen baseline differences further reduced power. 
 The control pamphlet was included to control for the attention effects of giving 
information materials and for any positive effects from introductory disease-related 
information which was included in the manual, along with the evidence information 
which was being trialled. However, the control pamphlet could have weakened the 
apparent effectiveness of the manual. The pamphlet contained some advice on dealing 
with exacerbations, stopping smoking, influenza vaccination, pulmonary 
rehabilitation, and home oxygen, even though research support for this advice was not 
provided. Ensuring control for non-specific aspects of the trial intervention may have 
meant that effects which would be seen in clinical practice were not demonstrated in 
the trial.
 25
 Though it was freely available in treatment settings, 83% of control 
participants said that they had not previously seen this pamphlet. The control 
condition did not therefore accurately reflect usual practice.  
Non-blinded interviewers could have influenced the results in spite of standardising of 
methods, though greater blinding is difficult with this type of study. 
Practice nurses and respiratory nurses have a growing role in behaviour change for 
self-management of chronic disease. By focussing on the doctor and patient as key 
figures in decision-making, the trial may not have accounted for the potential of 
nurses to increase patient participation in evidence-based decision making.  
Future work 
This study has shown that summaries of evidence, developed according to current 
best practice, are read by patients, including those with high socio-economic 
disadvantage. However, if these evidence summaries are to be used in decision 
making, they must not only be read but they must lead to behaviour change for 
patients and doctors.  
  
More needs to be known about what actually happens in the consultation to improve 
our understanding of how the informed patient might influence the doctor’s decision-
making as a basis for future interventions. Recent advice 
26,27
 proposes that 
behavioural interventions should be guided by theory and research relating to the 
operation of the intervention so that weak links in the causal chain can be identified 
and strengthened 
28 
  Our study showed the doctor patient consultation to be a weak 
link for interventions such as the COPD manual. In recent studies involving 
recordings of general practice consultations, most decisions were doctor-led rather 
than shared or patient led. 
29,30
  Research is now being conducted into doctors’ and 
patients’ perceptions of obstacles and facilitators to an increased role for patients,31,32 
and into doctor-targeted and patient-targeted interventions to increase patient 
participation in medical decisions.
33,34
  Studies such as these can be used to inform the 
design of future interventions which not only provide summaries of evidence to 
patients but facilitate their participation in decision-making and trigger treatment 
change.  
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 Figure 1 Causal steps linking delivery of manual to patient with evidence based care of COPD and study outcomes 
 
Sampling frame:
Patients discharged from or attending clinic at
participating hospitals, who potentially met
study criteria. Estimated at 1,400
Declined = 107
Control arm = 124Intervention arm = 125
Baseline data = 249
No reply = 355Joined study = 249
Invitations issued = 711
Completed to 12
months = 101
Completed to 12
months = 100
Lost from study = 25
(Withdrew = 12
Died = 8
Uncontactable = 6)
Lost from study = 23
(Withdrew = 10
Died = 10
Uncontactable = 3)
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Figure 2. Numbers  of participants at stages of study 
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Figure3. Completion of causal process steps for the manual  
 Table 1. Components of primary outcome measure 
Component Estimated initial rate/ target rate (%) Sample size required* 
Influenza vaccination current (within last 15 months) 80/95 88  
Bone density monitored (within last 42 months) 10/30 71  
Participation in pulmonary rehabilitation 25/45 98  
* Design was non-randomised but baseline differences between groups were not expected 
and standard sample size calculations were used. Table shows minimum sample size per 
arm for changes in proportion for components of the primary outcome measure with alpha set 
at 0.05 and power 80% (with continuity correction). 
  
Table 2. Baseline comparisons between intervention and control groups 
Characteristic Intervention group 
n=125 
Control group 
n=124 
Significance Test 
Demographics:     
i. Proportion (%) male 69/125 (55) 65/124 (52) 0.66  2 
ii. Proportion (%)  on oxygen at baseline 43/125 (34) 31/124 (25) 0.12  2 
iii. Proportion (%)  smoker at baseline 23/125 (18) 29/124 (23) 0.38  2 
iv. Mean age 73.6 73.1 0.64 t 
v. Mean years of formal education 10 10 0.18 t 
vi. Mean index of socioeconomic disadvantage for 
postcode 
1002.41 938.85 <0.001 t 
vii. % Living alone* 23/100 (23) 45/101 (45) 0.001  2 
Additional clinical baseline comparisons:     
viii.     Mean MISS score (possible range 1 to 7) 5.0 5.2 0.07 t 
ix a.    Mean CRQ dyspnea (possible range 1 to 7) 3.2 3.1 0.50 t 
ix b.    Mean CRQ fatigue (possible range 1 to 7) 3.5 3.6 0.70 t 
ix c.    Mean CRQ emotional function (possible range 1 to 7) 4.8 4.8 0.83 t 
Outcome  measures:     
1a.    Proportion (%) current flu vaccination 110/125 (88) 108/124 (87) 0.83  2 
1b.    Proportion (%) bone density test in last 3 1/2 yrs 39/125 (31) 39/124 (31) 0.97  2 
1 c.   Proportion (%)  ever attended pulmonary rehabilitation* 19/100 (19) 3/101 (3) <0.001 Fisher’s 
exact 
2. Mean CRQ mastery (possible range 1 to 7) 4.9 5.0 0.91 t 
3. Mean knowledge (possible range 0 to16) 12 11 0.10 t 
4a.     Mean MISS communication and comfort (possible range 1 
to 7) 
5.0 5.2 0.19 t 
4b.     Mean MISS rapport (possible range 1 to 7) 5.3 5.5 0.20 t 
5. Mean "Enough information" score (possible range 1 to 7) 4 4 0.72 t 
6. Mean state anxiety score (possible range 20 to 80) 32.2 32.1 0.97 t 
* Data available only for participants who completed to 12 months 
 Table 3. Outcome change scores at 12 months by socioeconomic disadvantage 
median split  
Group: 
 
Intervention 
 
Socioeconomic 
disadvantage 
level: 
Control 
 
Socioeconomic 
disadvantage level: 
Significance level for 
comparison of 
interventions and control 
groups* 
Socioeconomic 
disadvantage level: 
 Higher 
n=22 
Lower 
n=78 
Higher 
n=72 
Lower 
n=29 
Higher Lower 
1 a.   Flu vaccination rate (%) +7 +7 -1 +5 0.83 0.98 
1 b.   Bone density test within 3 yrs, rate (%) +6 +16 +7 +17 0.62 0.39 
1 c.    Pulmonary rehabilitation rate (%) +18 +12 0 +7 0.05 0.29 
8. CRQ mastery (mean) -0.1 0 0 0 0.70 0.50 
9. Knowledge (mean) 0 +1 +1 +2 0.82 0.75 
10. Enough information (mean) +1 +1 +1 +1 0.64 0.92 
11. MISS rapport (mean) -0.1 -0.1 -0.5 -0.1 0.72 0.26 
12. MISS Communication & comfort (mean) -0.2 0 -0.4 0 0.45 0.71 
13. Anxiety (mean) +2.0 +2.2 +2.0 +2.6 0.96 0.93 
*Using Analysis-of-covariance on change score, controlled for baseline measure and propensity score, except for 
pulmonary rehabilitation rate (1c) which was analysed using Poisson modelling with robust errors, adjusted for 
baseline rate. 
  
 
 
Table 4. Process survey results  
Group: 
 
 
 
Measure: 
Intervention 
 
Socioeconomic 
disadvantage level: 
Control 
 
Socioeconomic disadvantage 
level: 
Significance level for 
comparison of interventions 
and control groups* 
Socioeconomic disadvantage 
level: 
Higher 
n=22 
Lower 
n=78 
Higher 
n=72 
Lower 
n=29 Higher Lower 
Remember receiving  22(100) 71(91) 53(74) 22(76) 
0.005§ 0.04* 
Read part or all 20(91) 71(91) 46(64) 21(72) 
0.02§ 0.01* 
Read all 18(82) 51(65) 38(53) 16(55) 
0.02§ 0.33* 
Learned something 15(68) 42(54) 27(37) 11(38) 
0.01* 0.14* 
Referred back 13(59) 38(49) 14(19) 12(41) 
<0.001* 0.50* 
Very or quite helpful  19(86) 62(79) 34(47) 16(55) 
0.001§ 0.01* 
Talked to doctor 8(36) 34(44) 11(15) 7(24) 
0.03* 0.07* 
Treatment changed 2(9) 8(10) 2(3) 2(7) 
0.23§ 0.72§ 
* Chi square or, if numbers were small, 
§ 
Fisher’s exact test 
 
 
 
 
